0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Trimethoprim-Sulfamethoxazole or Pentamidine for Pneumocystis carinii Pneumonia in the Acquired Immunodeficiency Syndrome: A Prospective Randomized Trial

J. MARCUS WHARTON, M.D.; DIANA LEWIS COLEMAN, M.D.; CONSTANCE B. WOFSY, M.D.; JOHN M. LUCE, M.D.; WALTER BLUMENFELD, M.D.; W. KEITH HADLEY, M.D.; LESLIE INGRAM-DRAKE, A.B.; PAUL A. VOLBERDING, M.D.; and PHILIP C. HOPEWELL, M.D.
[+] Article and Author Information

Grant support: in part by Special Center for Research (SCOR) grant HL19155 from the National Heart, Lung, and Blood Institute.

Presented in part at the Annual Meeting of the American Thoracic Socie ty, Miami Beach, Florida, May 1984.

▸Requests for reprints should be addressed to Philip C. Hopewell, M.D.; Chest Service, Room 5K1, San Francisco General Hospital, 1001 Potrero Avenue; San Francisco, CA 94110.


San Francisco, California


© 1986 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1986;105(1):37-44. doi:10.7326/0003-4819-105-1-37
Text Size: A A A

Forty patients with the acquired immunodeficiency syndrome (AIDS) and their first episodes of Pneumocystis carinii pneumonia were assigned at random to receive either trimethoprim-sulfamethoxazole or pentamidine isethionate. The two groups did not differ significantly in the severity of pulmonary or systemic processes at enrollment. Five patients treated initially with trimethoprim-sulfamethoxazole and one patient treated initially with pentamidine died during the 21-day treatment period (p = 0.09, Fisher's exact test). No significant differences were seen between groups in rates of improvement, pulmonary function tests, or 67Ga uptake by the lungs in the survivors at completion of therapy. Adverse reactions necessitated changing from the initial drug in 10 patients in the trimethoprim-sulfamethoxazole group and 11 in the pentamidine group. Minor reactions occurred in all patients. In patients with AIDS, trimethoprim-sulfamethoxazole and pentamidine do not have statistically significant differences in efficacy or frequency of adverse reactions.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Journal Club
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)